Key Takeaways
- Targets three receptors simultaneously: GLP-1, GIP, and glucagon
- Phase 2: 24.2% average weight loss at 48 weeks (12mg dose)
- ~26% of Phase 2 participants lost 30% or more of body weight
- TRIUMPH Phase 3 program is currently underway
- Earliest realistic FDA approval: 2027 — timelines may shift
- Cannot be legally purchased, prescribed, or compounded in the US
What Is Retatrutide?
Retatrutide (LY3437943) is an investigational once-weekly injectable medication being studied for obesity and type 2 diabetes by Eli Lilly — the same company that makes Mounjaro and Zepbound. Its defining characteristic: it activates three hormone receptors simultaneously.
Most approved GLP-1 drugs target one receptor. Tirzepatide targets two. Retatrutide targets three: GLP-1, GIP, and glucagon. The glucagon component is what sets it apart — and may explain why its early weight loss data is higher than anything seen in previous GLP-1 drug development.
| Drug | Receptors | Avg Weight Loss | Approved? | Available |
|---|---|---|---|---|
| Wegovy (semaglutide) | GLP-1 | ~15% | Yes | Now |
| Zepbound (tirzepatide) | GLP-1 + GIP | ~20–22% | Yes | Now |
| Retatrutide | GLP-1 + GIP + Glucagon | ~24% | No (Phase 3) | 2027–2028 |
| CagriSema | GLP-1 + Amylin | 22.7% | No (Phase 3) | 2026–2027 |
| MariTide | GLP-1 / GIP block | ~20% | No (Phase 3) | 2027–2028 |
How the Triple-Receptor Mechanism Works
GLP-1 receptor activation is the foundation of modern obesity medicine. It slows gastric emptying, reduces appetite, and regulates blood sugar after meals.
GIP receptor activation enhances insulin response and may reduce nausea side effects compared to GLP-1 alone — which is part of why tirzepatide tends to be better tolerated than semaglutide in some patients.
Glucagon receptor activation is retatrutide's distinguishing mechanism. At the doses used in this drug, glucagon activation appears to increase resting metabolic rate and promote direct fat breakdown — particularly visceral fat (the fat surrounding internal organs). In simple terms: it burns fat even when you're not active.
Phase 2 Trial Results
The landmark Phase 2 trial enrolled 338 adults with obesity (without diabetes) and was published in the New England Journal of Medicine in 2023. Participants received different doses or placebo by weekly injection for 48 weeks.
Key results at the highest dose (12mg):
- Average body weight reduction: 24.2%
- Roughly equivalent to losing ~58 pounds from a 240 lb starting weight
- 26% of participants lost 30% or more of body weight
- Side effects similar to other GLP-1 medications — primarily nausea during dose escalation
Phase 2 is designed to identify whether a drug shows a signal worth studying further. Sample sizes are small and trial conditions are controlled. Phase 3 trials — which are much larger and more diverse — will determine whether these results hold up at scale. Many drugs show strong Phase 2 signals and then underperform in Phase 3.
Phase 3: The TRIUMPH Program
Eli Lilly launched a Phase 3 program called TRIUMPH that includes trials across multiple populations: adults with obesity, adults with type 2 diabetes, adolescents, and people with obesity-related cardiovascular disease and sleep apnea. Phase 3 results are expected through 2025–2026.
| Milestone | Estimated Timing |
|---|---|
| Phase 3 results published | 2025–2026 |
| NDA submission to FDA | 2026 (estimated) |
| FDA review period | 12–18 months |
| Earliest FDA approval | 2027 |
| Commercial availability | 6–12 months post-approval |
Zepbound (tirzepatide) achieves 20–22% weight loss through telehealth providers in most states — no insurance required for many options.
Retatrutide vs. Current Approved Medications
| Retatrutide | Wegovy | Zepbound | Ozempic | Mounjaro | |
|---|---|---|---|---|---|
| Status | Phase 3 | Approved | Approved | Approved | Approved |
| Mechanism | GLP-1/GIP/GCG | GLP-1 | GLP-1/GIP | GLP-1 | GLP-1/GIP |
| Avg weight loss | ~24% | ~15% | ~20–22% | ~12–15% | ~20% |
| Available now | No | Yes | Yes | Yes | Yes |
Side Effects
Based on Phase 2 data, the most common side effects are nausea, vomiting, diarrhea, and constipation — the same pattern seen across GLP-1 medications. Most people experience these most intensely during dose escalation. Long-term safety data from Phase 3 is not yet available.
What to Do While Waiting
Retatrutide is at minimum 2 years from availability. FDA-approved options — particularly tirzepatide (Zepbound) — are already achieving 20–22% average weight loss in large Phase 3 trials. That's within a few percentage points of what Phase 2 retatrutide showed, in longer and larger trials.
Starting with an approved medication today doesn't mean you can't switch when newer drugs become available. And two years of treatment with tirzepatide represents two years of health improvements you'd otherwise miss.
Explore other future GLP-1 medications, compare them at the drug comparison hub, or see the full approval timeline.
Frequently Asked Questions
Is retatrutide available to buy?
No. Retatrutide is investigational and not FDA-approved. It cannot be legally purchased, prescribed, or compounded in the US. Any product claiming to be retatrutide is not a legitimate pharmaceutical.
How much weight can you lose on retatrutide?
Phase 2 trials showed an average of 24.2% body weight loss at 48 weeks at the highest dose (12mg). About 26% of participants lost 30% or more. These are Phase 2 results — Phase 3 data will be more definitive.
When will retatrutide be approved?
Based on current TRIUMPH Phase 3 trial timelines, the earliest realistic FDA approval window is 2027. Phase 3 results are expected 2025–2026, followed by NDA submission and a 12–18 month FDA review. Timelines frequently shift.
What is the difference between retatrutide and tirzepatide?
Tirzepatide targets two receptors: GLP-1 and GIP. Retatrutide adds a third — glucagon. The glucagon component is believed to increase resting metabolic rate and promote fat breakdown, which may explain retatrutide's additional weight loss advantage in Phase 2.
What should I do while waiting for retatrutide?
FDA-approved options — particularly tirzepatide (Zepbound) — achieve 20–22% average weight loss and are available now through telehealth providers in most states. Starting treatment now doesn't prevent switching later.
FDA-Approved Options Are Available Right Now
Tirzepatide (Zepbound) — the closest approved drug to retatrutide in efficacy — is accessible through telehealth providers in most states, often without insurance.
Take Quiz — Free